Race Oncology
Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).
ASX Announcements
| Date | Title | |
|---|---|---|
| 06/09/2019 | Notice of General Meeting/Proxy Form | Download |
| 27/08/2019 | Appendix 3B | Download |
| 27/08/2019 | Cleansing Notice | Download |
| 23/08/2019 | Appendix 4E & Annual Report | Download |
| 23/08/2019 | Appendix 4G | Download |
| 20/08/2019 | Change in substantial holding | Download |
| 20/08/2019 | Appendix 3B | Download |
| 20/08/2019 | Cleansing Notice | Download |
| 20/08/2019 | Information Required under ASX Listing Rule 3.10.5A | Download |
| 20/08/2019 | Becoming a substantial holder | Download |
ASX: RAC
Price
Latest News
Prominent biotech investor leads investment in Race
Race Oncology Limited is pleased to announce the successful completion of a $1.45 million
Race announces additional US Patent for Bisantrene
Race Oncology has announced it has secured a new patent on its cancer drug, Bisantrene, from
Race’s Israel trial treats first patient with Bisantrene
Race Oncology is pleased to announce the first patient has been treated with Bisantrene in the
Don't miss important updates
Get the latest news & announcement and stay up-to-date.